S32 is a venture capital firm that invests in early-stage companies across various technology sectors, including software, data, artificial intelligence, enterprise software, cybersecurity, quantum computing, computational biology, and healthcare. Their strategy focuses on identifying innovative solutions and providing capital, strategic guidance, and operational support to help entrepreneurs scale their businesses.
36% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (6 deals in the last 12 months). Average disclosed round size is $119.8M (across 10 rounds with reported amounts).
Portfolio
11
Fund Size
$2B
Top Stage
Series C
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| AAutoscience | Seed | $14M | Mar 2026 |
 Culture Biosciences | Series C | — | Dec 2025 |
 Black Forest Labs | Series B | $300M | Dec 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Sola Security | Series A | $35M | Sep 2025 |
 Infleqtion | Series C | $100M | Jun 2025 |
 Sola | Seed | $30M | Mar 2025 |
 TollBit | Series A | $24M | Oct 2024 |
 Basecamp Research | Series B | $60M | Oct 2024 |
 Pomelo | Series B | $40M | Jan 2024 |
 Humans& | Seed | $480M | — |
Top Co-Investors
SV Angel2 shared
Nvidia2 shared
General Catalyst2 shared
Glilot Capital Partners2 shared
OrbiMed1 shared
ARCH Venture Partners1 shared
Frazier Life Sciences1 shared
Lifeforce Capital1 shared
Balyasny Asset Management1 shared
Cormorant Asset Management1 shared
Axon Partners Group1 shared
Kite, a Gilead Company1 shared
Northpond Ventures1 shared
Cultivian Sandbox1 shared
GV (Google Ventures)1 shared
Emerson Collective1 shared
Forerunner Ventures1 shared
DCVC1 shared
Human Ventures1 shared
Felicis Ventures1 shared
Last updated: 12 April 2026